Effect of Beta-Blockers on Mortality after Myocardial Infarction in Adults with COPD

JANUARY 16, 2014
Jennifer Quint, clinical lecturer in epidemiology at the London School of Hygiene and Tropical Medicine, and Liam Smeeth, professor of clinical epidemiology at the London School of Hygiene and Tropical Medicine, discuss their BMJ study of UK COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.



SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.